<a href="http://dir.yahoo.com/Science/Biology/Biotechnology/">Arizona
Biotech</a> is now listed in Science > Biology > Biotechnology in the
Yahoo! Directory


<a href="http://dir.yahoo.com/new/20050609/Science/">Ariona
Biotech</a> Yahoo! Directory - New Additions in Science for Thursday
Jun 9, 2005

Directory > Science
Directory > Biology > Biotechnology
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a> -
includes news and information on Arizona Biotechnology, genomics,
biotech companies, genetic engineering, biotech research, and biology.

<a href= http://www.arizonabiotech.com/ >Arizona Biotech</a>



http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Biotech Research Breakthroughs, Collaborations, and Economic
Incentives to Be Announced at BIO 2005



A number of state and international economic development agencies
and private companies will make announcements to the press at a
special venue during the BIO 2005 Annual International Convention,
June 19-22 at the Pennsylvania Convention Center in Philadelphia.

The press conferences will spotlight scientific advancements, new
research agreements, and biotech business opportunities around the
world.  The schedule of press conferences, listed in chronological
order, includes the following:

     * Government of India -- Recent Policy Developments
       Will Make India a Hotbed for Biotech
       Kapil Sibal, Indian Minister for Science & Technology,
       Amar Singh, Member of Parliament, and others will
       outline why India is fast emerging as a significant
       biotechnology hotbed in the Asia-Pacific region.
       Sunday, June 19 at 10:00 am, Room 203B
       Contact: Kapil Sibal, 24 64 1074

     * Queensland, Australia -- Biotechnology Breakthroughs
       The Honourable Peter Beattie, MP, Premier of
       Queensland, will announce breakthroughs in research and
       development within Queensland's biotechnology industry.
       His announcement will highlight R&D funding
       commitments, new industry partnerships, new research
       collaborations, and significant policy decisions, such as the
       Biodiscovery Bill.
       Monday, June 20 at 9:00 am, Room 203B
       Contact: Tina Radburn, (213) 346-0090,
tina.radburn@...

     * BioAdvance -- Greater Philadelphia Life Sciences
       Study Findings
       BioAdvance will announce findings of a first-ever look at
       the Greater Philadelphia area's competitive position within
       the life sciences industry.  BioAdvance will release a June
       2005 Milken Institute study, titled "The Greater
       Philadelphia Life Sciences Cluster: An Economic and
       Competitive Assessment."
       Monday, June 20 at 10:00 am, Room 203B
       Contact: Ellen Semple, (215) 966-6207, esemple@...

     * Victoria, Australia -- New Biomedical Announcements,
       Plus Latest Results in the Kangaroo Genomics Project
       Victoria Government Premier Steve Bracks, Treasurer
       John Brumby and Minister for Health Bronwyn Pike will
       deliver major biomedical announcements and the latest
       results in kangaroo genomics research projects.  Victoria is
       partnering with the US NIH on sequencing the kangaroo genome.
       Monday, June 20 at 10:00 am, Room 204A
       Contact: Trish Vardon, +61 (0)3 9651 9236,
trish.vardon@...

     * British Columbia -- Hot Opportunities in North America
       British Columbia Premier Gordon Campbell will announce
       economic development incentives for the biotechnology
       industry in Canada.
       Monday, June 20 at 11:00 am, Room 203B
       Contact: Linda Thorstad, (604) 761-5046,
lthorstad@...

     * Singapore -- The Biopolis of Asia
       Singapore is dedicated to enhancing human healthcare as
       one of the world's most preeminent life sciences hubs.  The
       Singapore Economic Development Board will emphasize
       opportunities that currently exist in Singapore as a base for
       R&D investment and as a strategic location for Biomedical
       Sciences manufacturing.
       Monday, June 20 at 12:00 pm, Room 203B
       Contact: Daphne Teo, +65 6235 4495, teod@...

     * Invitrogen -- A New System for Disease Research
       Invitrogen will announce new research technologies geared
       toward specific disease models and pathways.  Invitrogen
       will introduce a system that ties its technologies together to
       target applications and pathways.
       Monday, June 20 at 2:00 pm, Room 203B
       Contact: Gregory L. Geissman, (760) 476-7032,
       gregory.geissman@...

     * Wyeth & Dublin City University -- Collaboration on
       Advanced Technologies for Protein Expression
       Wyeth and Dublin City University have entered into a
       collaborative research agreement, with funding support
       from the Science Foundation of Ireland, to investigate gene
       expression pathways of cultured mammalian cells relevant
       to their industrial use in biopharmaceutical production.  The
       project will involve the use of genomics and proteomics
       technologies in the identification of genes expressed in
       Chinese hamster ovary cells that are important in
       supporting outstanding cell growth and protein
       productivity in production bioreactor cultures.
       Tuesday, June 21 at 11:00 am, Room 203B
       Contact: Gerald V. Burr, (484) 865-5138, burrg@...

     * Commonwealth of Massachusetts -- Joint Scientific
       Research Collaborations between Massachusetts and
       the Ministry Of Education, University, and Research of
       the Italian Republic
       Massachusetts Governor Mitt Romney will sign a
       Memorandum of Understanding designed to further the
       establishment of bilateral networks and partnerships and to
       facilitate joint scientific, medical research and
       biotechnology development projects in Massachusetts and
       Italy.
       Tuesday, June 21 at 1:00 pm, Room 203B
       Contact: Amy Speer, (617) 788-3636, Amy.Speer@...

     * Biotechnology Industry Organization -- The Value of
       Biotech Healthcare Therapies
       Amit Sachdev, BIO's Executive Vice President, Health,
       and Jayson Slotnick, BIO's Director, Medicare
       Reimbursement & Economic Policy, will release the
       results of a study on the value of biotech therapies.
       Tuesday, June 21 at 2:00 pm, Room 203B
       Contact: Jayson Slotnick, (202) 962-9200, jslotnick@...

     * Montgomery County, Md. -- Maryland Welcomes
       Britain's Xceleron
       Xceleron, the world's foremost company using the
       nanotechnology of accelerator mass spectrometry in drug
       development, will announce its new North American
       Headquarters, to be located in Montgomery County,
       Maryland.  Xceleron's technologies have been proven to
       speed drug development and reduce attrition rates.
       Tuesday, June 21 at 3:00 pm, Room 203B
       Contact: Joseph H. Shapiro, (240) 777-2000,
       joseph.shapiro@...

     * MDS Pharma Services -- Biomarker Alliance Launch
       Dr. Jean W. Lee, Research Fellow, and Fred Pritchard,
       vice president, Drug Development Programs, of MDS
       Pharma Services will announce the formation of a
       biomarker alliance among a coalition of commercial and
       academic groups.
       Wednesday, June 22 at 11:00 am, Room 203B
       Contact: John F. Kouten, (908) 281-6099

The complete up-to-date schedule of press conferences can be viewed
on BIO's web site, at
bio.org/events/2005/media/presscon.asp.


Media registration for the BIO 2005 Annual International Convention
is complimentary for credentialed members of the news media.  Only
reporters and editors working full-time for print or broadcast news
organizations may register on site with valid, current media
credentials (i.e. official picture identification from the employing
news organization).  Everyone attending the conference must present
valid photo identification to gain admittance.

Without proper, approved credentials, on site media registration
will be denied.  Freelance journalists, college publications and Web-
based publications may not register on site at the conference.
Marketing, public relations executives, analysts, consultants,
authors, and researchers may not register as media.  BIO reserves
the right to limit the number of admission approvals from the same
publication or news outlet.

     BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations.  BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.


SOURCE Biotechnology Industry Organization
Web Site: bio.org


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneur.com/
<a href="http://www.arizonaentrepreneur.com/">Arizona Entrepreneur</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Supreme Court Protects Pharmaceutical Research

Heller Ehrman Represented Merck KGaA In a Victory That Will Have an
Enormous Impact on the Pharmaceutical Industry


NEW YORK, June 13 -- The U.S. Supreme Court ruled today that the
pharmaceutical companies have a broad immunity from patent
infringement claims when they engage in research on promising new
drug candidates. In a unanimous opinion authored by Justice Antonin
Scalia, the Supreme Court held that the Federal Circuit had erred
when it drastically limited the protection of the FDA safe harbor,
applying it only to the late-stage testing on human patients.

"This was a grand slam homerun for patients and for drug innovators.
The Supreme Court gave drug companies and researchers enormous
latitude to conduct the testing necessary to bring promising
therapies to needy patients. It means that researchers will not have
to sit on their hands for a decade when they have discovered a
promising drug, but rather, without skipping a beat, can conduct the
experiments they need to conduct to make sure the drug gets to sick
patients as soon after patent expiration as possible."



-- E. Joshua Rosenkranz, Heller Ehrman LLP

The case, Merck KGaA v Inegra LifeSciences is the most significant
patent infringement ruling to confront the biotech and
pharmaceutical industries in a generation.

WHO:   Attorney E. Joshua Rosenkranz
*  Attorney E. Joshua Rosenkranz presented the oral argument, on
behalf of Merck KGaA, before the U.S. Supreme Court in April 2005.


http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Pennsylvania Department of Community and Economic Development


PA DCED Secretary Announces Five Economic Development and Technology
Investment Projects That Will Create Nearly 500 Biosciences Jobs in
Pennsylvania

HARRISBURG, Pa., June 13

Pennsylvania Department of Community and Economic Development (DCED)
Secretary Dennis Yablonsky today announced Governor's Action Team
(GAT) projects for five Biosciences companies that were offered
approximately $5 million in state assistance to create and retain
nearly 500 jobs in Pennsylvania.


"The bioscience industry is transforming the commonwealth's economy
by supporting new companies, creating jobs and contributing to
community growth," Yablonsky said. "Today's announcements
demonstrate the commonwealth's commitment and tradition to
innovation through our forward thinking and dedication to the life
sciences industry. Projects like these ensure our continued growth
and success in this constantly evolving industry throughout
Pennsylvania and beyond."

Yablonsky announced the following GAT projects:

Agentase LLC is expanding its Allegheny County operations by
relocating to a new facility in Harmar Township. The chemical
engineering company completed the Research & Development (R&D) phase
for its new products and needs to relocate to a facility with wet
chemistry lab space. At least 54 jobs will be created within three
years and 22 existing employees will be retained. The Governor's
Action Team (GAT), economic development professionals who report
directly to Gov. Edward G. Rendell and Yablonsky, and the Allegheny
County Department of Economic Development worked with Agentase on
this project. DCED offered the company a $328,300 funding package
that includes: a $200,000 Small Business First (SBF) loan; a $50,000
Opportunity Grant; $24,300 in Job Training Assistance (JTA); and
$54,000 in Job Creation Tax Credits (JCTC). Agentase is focused on
the development and implementation of biocatalysts. Its products
include anti-chemical warfare/terrorism sensors and pesticide
remediation.

Charles River Laboratories has outgrown its current Exton facility
and plans to relocate to a new 60,000-80,000-square-foot facility in
southeastern Pennsylvania. A location has not yet been determined.
The company, a provider of solutions that advance the drug discovery
and development process, will create at least 36 jobs within three
years and retain 92 existing employees. DCED offered the company a
$1.08 million financial package that includes: $450,000 Machinery
and Equipment Loan Fund (MELF); $300,000 Opportunity Grant; $150,000
JTA; and $180,000 JCTC. Charles River Laboratories' products and
services are designed to enable its clients to bring drugs to market
faster and more efficiently.

Integrated BioSciences Inc. (IBS) is expanding its existing
Lewisberry, York County facilities and infrastructure by purchasing
additional equipment and hiring new employees. At least 65 jobs will
be created within three years and the company, which is a complete
contract manufacturer of medical devices, automated equipment
and "box build" electronics, will retain 22 existing employees. DCED
offered the company a $705,000 funding package that includes: a
$500,000 loan through MELF; a $75,000 Opportunity Grant; and
$130,000 JCTC. IBS is an FDA registered, ISO 9001:2000 certified
manufacturer that offers total project management for class I and II
medical devices for companies looking to outsource the manufacture
of their products, automated equipment or entire manufacturing
programs.

Isolagen Inc. has expanded operations by relocating its Texas
headquarters and R&D to its existing Exton, Chester County,
facility. The company, which specializes in the development and
commercialization of cellular therapies for soft and hard tissue
regeneration, will create at least 140 new jobs within three years.
DCED offered Isolagen a $1.7 million financial package that
includes: a $500,000 loan through MELF: a $400,000 Opportunity
Grant; $100,000 JTA; and $700,000 JCTC. The company's technology
process has potential applications in cosmetic dermatology, cosmetic
surgery, periodontal disease, reconstructive dentistry and other
therapies. Isolagen has five secured patents and five additional
patents pending.

NanoDynamics Inc. has four existing business units and is creating a
new division in the City of Pittsburgh - ND Life - in collaboration
with the McGowan Institute of Regenerative Tissue. At least 50 jobs
will be created by the company, which will leverage existing
expertise in nanotechnology-based products to address needs and
opportunities in the life sciences marketplace. DCED offered
NanoDynamics a $1.15 million funding package that includes: a
$500,000 loan through MELF; a $200,000 loan through SBF; a $200,000
Opportunity Grant; $100,000 JTA; and $150,000 JCTC. NanoDynamics is
a leading manufacturer of nanomaterials to improve the form,
function and performance of industrial and consumer products. The
new division is located in the Pittsburgh Life Sciences Greenhouse.

"Today's announcements further demonstrate the commonwealth's
leadership in supporting this important industry," said Fritz
Bittenbender, president of Pennsylvania Bio, the state biosciences
trade association. "From tradable R&D tax credits, to the Life
Sciences Greenhouse Initiative, venture capital programs and more,
Pennsylvania has created an environment that helps grow and sustain
bioscience companies. With the continued support of the governor and
the legislature, Pennsylvania will be a global leader in the
biosciences."

BIO International handpicked the commonwealth as the 2005 host state
for the BIO 2005 Annual Conference, taking place June 19-22 in
Philadelphia.

For information on DCED funding, visit http://www.newpa.com. For
additional information on Pennsylvania Bio, visit
http://www.pennsylvaniabio.com.

For information on each of the five companies announced today, visit
the following websites: http://www.agentase.com;
http://www.criver.com; http://www.ibiosci.com;
http://www.isolagen.com; http://www.nanodynamics.com.

CONTACT: Penny Kline, Pennsylvania Department of Community and
Economic Development, +1-717-783-1132.




---------------------------------------------------------------------
-----------
Source: Pennsylvania Department of Community and Economic Development

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.stoneagedesigns.net/
http://www.navending.com/
http://www.sell2us.net/
http://smsac.blogspot.com/
http://www.auntiebelhams.com/
http://www.serenitygroup.com/
http://www.yainc.net/

Biotechnology Laboratory Technician Certificate
http://www.csusm-es.org/biotech/

CSUSM - Extended Studies - Biotechnology Laboratory Technician
Certificate Program

  Train for a New Career in Biotechnology! Program begins January 18,
2005.

National and local trends indicate that there is a promising
employment picture for individuals with specific training in
biotechnology. While biotech-related jobs in 2003 jumped more than
12.4% over the previous year, it is projected that the San Diego
biotech workforce will grow on a faster-than-average basis (17.5%)
for this decade (San Diego Economic Bulletin, December 2003 and
Nature, December 11, 2003). Inherent in this workforce growth is the
increasing need for qualified laboratory technicians.

This specialized Biotechnology Laboratory Technician Certificate
program is designed to:

Provide students with a foundation in the knowledge and techniques
needed to earn entry-level positions as lab technicians in the
growing biotechnology field
Train laboratory personnel for careers and jobs as laboratory
technicians and/or research assistants
Concentrate on the laboratory techniques most commonly used by firms
in their research,manufacturing, and quality control laboratories
Provide industry employers with a workforce-ready pool of well-
trained lab technicians, Quality Assurance and research /
manufacturing assistant






This program provides an overview of the industry and the functions
of biotechnology and pharmaceutical laboratories in research,
manufacturing and quality control. Emphasis on the industry, the
role of biotechnology companies and the process of discovery and
development of new products. Also covered are federal regulations
with emphasis on Good Laboratory Practices (GLP) and Good
Manufacturing Practices (GMP).

The 17-semester unit certificate can be completed in one full year,
provided necessary prerequisites
have been completed. Courses are drawn from the regular Cal State
San Marcos catalog and include:

BIOL 359 Biotech/Pharmaceutical Industry Labs (3 units)
BIOL 355 Molecular Biotechnology (4 units)
BIOL 356 Cellular Biotechnology (4 units)
CHEM 351 Biochemistry (3 units)
BIOL 358 Computer Skills for Biotechnology (3 units)
****Biotech/Pharma Industry Laboratories (BIOL 359)

This exciting new course will provide you with a comprehensive
overview of the industry and the functions of biotechnology and
pharmaceutical laboratories in research, manufacturing and quality
control. Emphasis is on the industry, the role of biotechnology
companies and the process of discovering and developing new
products. Also covered are federal regulations with emphases on Good
Laboratory Practices (GLP) and Good Manufacturing Practices
(GMP).This course may be taken as a "stand alone" course for
individuals who simply want an introduction to the biotech/pharma
industry, or as the first course in the Biotechnology Laboratory
Technician Certificate of Competence. No prerequisites; no program
application required. May be used as an elective for the CSUSM
biology degree.

Course No: BIOL 359
Fee: $600
Dates: Tuesdays, January 18 – April 5
Saturdays, January 22 and April 16
Times: 5:30 am - 8:30 pm (Tuesdays) and 8:30-3:00 pm (Saturdays)
Units: Three Semester Units (degree applicable)
Location: Please call the Extended Studies office at (760) 750-4020
for classroom location.
Facilitator: Al Kern, Director of Biotechnology, Cal State San
Marcos
Instructors: Program features a wide variety of industry leaders and
content experts.

For more information on the certificate program and to receive an
application packet, contact Extended Studies at (760) 750-4020.


http://www.arizonabiotech.com/

http://groups.yahoo.com/group/biotech-news/

http://smsac.blogspot.com/

More than 45 Delegates from the New Zealand Biotechnology Industry
Highlight New Zealand Innovation and Global Connectedness at BIO
2005

      BIO 2005 Annual Convention


   Over 150 Years of Life Sciences R&D Has Produced a Rapidly Growing
Biotech Industry Addressed to Health and Wellness, Industrial
Biotech, Agriculture, Forestry and More

More than 150 years of life sciences research and technological
innovation, combined with strong global partnerships, and a public-
private collaborative approach to business have given New Zealand
one of the world's fastest growing biotechnology industries. Today
New Zealand biotechnology applications range beyond agriculture to
add medicine, human health, wellness and performance, industrial
biotechnology, forestry, biosecurity, and environmental
applications.

To promote awareness of New Zealand's growing global presence in
biotechnology, the Honorable Pete Hodgson, New Zealand Minister of
Commerce and ex-Minister of Research, Science and Technology will
lead a delegation of 47 companies and organizations to the BIO 2005
conference, taking place in Philadelphia, PA from June 19 - 22.
Through its internationally oriented biotechnology industry and its
presence at BIO 2005, New Zealand is reaching out to partner with
leading U.S. and international research institutions and
universities, companies, and state agencies.

New Zealand Pavilion

The New Zealand Government's economic development agency New Zealand
Trade and Enterprise (NZTE) will host a pavilion in the BIO 2005
Exhibition Hall. The pavilion will showcase a variety of New Zealand
research initiatives and companies in the areas of human medicine,
health and wellness, agricultural biotechnology, industrial
biotechnology and support organizations. The pavilion will include a
meeting area for networking and one-on-one meetings during the
conference. NZTE will co-host with the Australian Pavilion a special
exhibit hall event on Tuesday June 21, 2:00 - 4:00 pm, featuring
fine wines from New Zealand and Australia. The New Zealand Pavilion
is located in Hall C, Stands 749-856.

New Zealand Country Seminar

On Sunday June 19, International Day presenters for New Zealand will
include Minister Hodgson, along with Chris Boalch, Director of
Biotechnology, NZTE; Richard Furneux, Ph.D., CEO of GlycoSyn, an
Industrial Research Ltd company focused on glycobiology; Larry
Ellingson, CEO of Protemix USA, a New Zealand founded
biopharmaceutical company; and Howard Moore, Executive Director of
the recently founded venture firm, BioPacificVentures. Together they
will provide an overview of the New Zealand biotech industry and
business environment, including government initiatives planned to
grow the industry, as well as the New Zealand industry's expanding
international linkages.

The New Zealand Minister of Commerce, Hon. Pete Hodgson, said, "Much
of New Zealand's wealth has been built on a proven ability to add
value to natural resources by applying biological knowledge. Now
unique approaches to biotechnology pioneered in New Zealand are set
to have a major impact on the way we all deal with health and
environmental issues.

"The New Zealand biotech sector has firm backing from the New
Zealand Government which recognises its importance to the economy.
It is working with the New Zealand biotechnology community to
implement a detailed strategy to put in place the necessary
infrastructure to promote success on a global scale."

New Zealand Companies at BIO2005

Representatives of some of New Zealand's leading biotechnology
companies, as well as scientists from cutting edge research programs
at the country's Crown Research Institutes and Universities, will
represent the nation's outstanding capabilities and global research
at BIO2005. Just a few of the New Zealand companies represented at
BIO include:

-- Proacta and Protemix are two companies that illustrate well the
global connectedness of New Zealand biotechnology. Taking advantage
of New Zealand innovation, scientific know-how and low cost of
research, these two companies are among those who have expanded
operations to the United States for access to larger patient
populations and markets. Proacta is developing treatments for cancer
that take advantage of the oxygen-poor environment in tumors.
Protemix is engaged in the development of a novel treatment to
repair heart damage in patients with diabetes, as well as other
therapies for cardiovascular disease, diabetes and other metabolic
conditions.

-- Lactopharma and Ovita are two companies whose research
demonstrates New Zealand's ability to mine leading agricultural
research for new human therapeutic applications. Lactopharma is
developing applications of lactoferrin, a milk-derived protein with
both anti-inflammatory properties and the ability to promote bone
formation and inhibit bone absorption. Ovita's research on muscle
development and twinning in sheep offers opportunities for
development new treatments against muscle wasting and to aid
fertility in humans.

-- Pacific Edge Biotechnology Ltd, a biomedical company with a
strategic focus on "human health and wellness" combines state-of-the-
art molecular biology and micro array technology with world-class
tissue banks and clinical data. These resources, combined with
proprietary analytical software, enable the company to identify
unique gene signatures of disease.

-- IRL - With a focus on creating new technologies, Industrial
Research Ltd (IRL) draws from New Zealand science & technology
platforms to create globally competitive products for customers
worldwide. This focus includes a core emphasis within biotechnology.
For example, one of IRL's key business units, GlycoSyn, is drawing
from world-class expertise in carbohydrate chemistry to collaborate
with Albert Einstein College of Medicine in New York. This
partnership has enabled them to produce novel treatments for cancer
and autoimmune diseases that have led to further clinical
development with companies in the United States and Australia. A
separate spin-out company from Industrial Research, IRL Biopharm,
manufactures many of the potent molecules used as "warheads" in
anticancer antibodies under development by a major US biotech
company.

-- Neuren Pharmaceuticals is a biopharmaceutical company whose
product pipeline is applicable to two of the world's largest and
fastest growing therapeutic markets: neuroprotection and metabolism.
The company has many U.S. and other global collaborations, including
one with Walter Reed Army Institute of Research focused on
neuroprotectant treatments and traumatic brain injury.

For more information on New Zealand and its biotechnology industry,
as well as its participation in BIO 2005, please visit
www.nzte.govt.nz/bio2005.




http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Generex Biotechnology Presents Oral-lyn(TM) Clinical Trial Results

Company presents at the American Diabetes Association 65th
Scientific Sessions

TORONTO,

Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in
the area of buccal drug delivery, today announced clinical trial
results in respect of Oral-lyn(TM), the Company's proprietary oral
insulin buccal spray formulation, presented at the 65th Annual
Meeting & Scientific Sessions of the American Diabetes Association
held June 10 - 14, 2005 in San Diego.

Generex clinician Dr. Jaime Guevara-Aguirre presented a poster in
the Clinical Therapeutics/New Technology -- Insulin Delivery Systems
category titled "A Series of Open-Label Studies Comparing Various
Formulations of Oral-lyn(TM) Propellant Spray in Patients with Type-
1 Diabetes Mellitus" (co-authored with M. Guevara and J. Saavedra).

During the normal drug development process and besides evaluating
Oral-lyn(TM) against its active comparator, it was necessary to test
preparations with different insulin concentrations or different
ratios of the excipients included in the Oral-lyn(TM) formulation.
In Dr. Guevara's study, the glucodyanmic (GD) profiles induced by
single pre-prandial versus pre- and post-prandial split doses of
Oral-lyn(TM) were compared to the GD profile of Humulin-R in a 3-day
(4 hours per day) open-label study performed in patients with Type-1
diabetes. In a second experiment, Dr. Guevara tested the relative
efficacy of various Oral-lyn(TM) preparations in a series of similar
4-hour open label studies performed in the same individuals with a
view to determining the most appropriate Oral-lyn(TM) preparation
for longer term trials.

In the first experiment, Oral-lyn(TM), in either a single pre-
prandial dose or in a split-dose fashion, was administered to 6
patients with Type-1 diabetes. The corresponding GD profiles were
compared to the GD profiles induced by the administration of the
active comparator (subcutaneous injection of Humlin-R) 30 minutes
prior to the same test meal. The study determined that a pre- and
post-prandial split-dose of Oral-lyn(TM) was better than a pre-
prandial single dose and comparable to the GD profile induced by
Humulin-R.

The second experiment included a series of open-label studies at
which the same 6 patients with Type-1 diabetes received, in
different days, single does of each preparation of Oral-lyn(TM) in a
split-dose regimen with 5 puffs before and 5 puffs after the test
meal. After evaluation of the GD profiles of the various
preparations, Dr. Guevara was able to identify the preparation that
exhibited the best GD profile for use in longer term trials.

In addition, Generex clinician Professor Itamar Raz published a
paper in the Abstract Book for the 65th Annual Scientific Sessions
titled "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type-
2 Diabetes Maintained on Glargine + Meformin -- A Comparison with
Placebo" (co-authored with A. Dubinsky, M. Kidron and J. Wainstein).

The purpose of the Professor Raz study was to determine the
metabolic effect of Oral-lyn(TM) at mealtime on a long-term basis
(12 weeks) in patients with Type-2 diabetes maintained on once-a-day
subcutaneous Glargine insulin injection therapy at bedtime and
Metformin. The primary hypothesis was that Oral-lyn(TM) can be used
safely at mealtimes and will improve 7 point glucose profiles,
fructosamine and the baseline HbA1c levels 12 weeks after treatment.

This was a randomized, double-blind, long-term (12 weeks) study in
26 patients with Type-2 diabetes (male or female) with poorly
controlled blood glucose maintained on once a day s.c. Glargine and
Metformin. After the initial screening visit, subjects maintained
their regular treatment for two weeks as a run-in period. Following
the training of the Oral-lyn(TM) device operation and dosing
schedules, they were divided into two groups. One group had 7 puffs
of Oral-lyn(TM) TID, and the other group had 7 puffs of placebo TID.
Both groups took the puffs 10 minutes before mealtime in addition to
their regular treatment. In cases where self-glucose values were
above 12mmol/L before any meal or before bedtime, an additional 7
puffs were added. Each subject had routine blood chemistry and HbA1c
as well as fructosamine levels at the beginning of the study and at
the end of every month during the study period. Beginning with the
initial screening visit, each subject had to monitor his/her blood
glucose at least three times a day and once a week for a 7-point
profile.

The interim results, after 8 weeks of treatment, showed no change in
fasting glucose while in post-prandial glucose there was a 15.4%
reduction in the Oral-lyn(TM) group versus 3.9% elevation in the
placebo group. Furthermore, the study found a reduction of
fructosamine in the Oral-lyn(TM) group of 6.4% versus 3.6% in the
placebo group and for HbA1c there was a 6.6% reduction in the Oral-
lyn(TM) group versus 3.4% in the placebo group. The effective post-
prandial trend can be seen clearly, although the results are not
statistically significant. This may be partially due to the short
time period and small sample size of the study.

The study concluded that in patients with Type-2 diabetes maintained
on Glargine and Metformin, Oral-lyn(TM) was especially effective in
controlling post-prandial glucose excursions.

About Generex

Generex (http://www.generex.com) is engaged in the research and
development of drug delivery systems and technologies. Generex has
developed a proprietary platform technology for the delivery of
drugs into the human body through the oral cavity (with no deposit
in the lungs). The Company's proprietary liquid formulations allow
drugs typically administered by injection to be absorbed into the
body by the lining of the inner mouth using the Company's
proprietary RapidMist(TM) device. The Company's flagship product,
oral insulin (Oral-lyn(TM)), is in late stage clinical trials around
the world.

Safe Harbor Statement: This release and oral statements made from
time to time by Generex representatives concerning the same subject
matter may contain "forward- looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements can be identified by introductory words such
as "expects," "plans," "intends," "believes," "will," "estimates," "f
orecasts," "projects" or words of similar meaning, and by the fact
that they do not relate strictly to historical or current facts.
Forward- looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause
actual results to differ from forward-looking statements, including
inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward- looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex
cannot be sure when or if it will be permitted by regulatory
agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements
regarding the expected timing of clinical trials cannot be regarded
as actual predictions of when Generex will obtain regulatory
approval for any "phase" of clinical trials. Generex claims the
protection of the safe harbor for forward-looking statements that is
contained in the Private Securities Litigation Reform Act.




---------------------------------------------------------------------
-----------
Source: Generex Biotechnology Corporation



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Kreatech Biotechnology Launches a Series of ULS arrayCGH Labeling
Kits Array Based Comparative Genomic Hybridization (CGH) Analysis

     AMSTERDAM,

New "ULS(TM) arrayCGH Labeling Kits" for Direct, Non-enzymatic
labeling of genomic DNA for microarray based comparative genomic
hybridization (arrayCGH) analysis

     Kreatech Biotechnology BV announces the launch of a series of ULS
arrayCGH labeling kits offering its' proprietary ULS labeling
molecule bound to a choice of fluorescent dye pairs that have been
licensed by Kreatech including dyes from GE Healthcare/Amersham
(CyDyes), Perkin Elmer (Cyanine Dyes) and Dyomics (DYDyes). The
complete labeling kits include unique purification columns
(KREApure), blocking buffer (KREAblock) and hybridization buffers.

     The ULS labeling of nucleic acids is a robust, one-step
procedure that is completed within 30 minutes. "The possibility of
analyzing genomic DNA directly without the need to amplify is a very
attractive feature to many researchers, not only does it save time
but it also removes the potentially biasing enzymatic step that is
currently required in order to label genomic samples" according to
Ted van der Lende, Director of product development.

     The Universal Linkage System - ULS(TM) - is a proprietary
labeling technology that has been optimized for arrayCGH analysis on
DNA arrays. The ULS arrayCGH labeling kit has the unique feature of
allowing the user to label genomic DNA directly in a one step
labeling reaction (30 minutes), avoiding the need for a potentially
biasing enzymatic step. This results in more accurate data as well
as saving time and money. The ULS labeling efficiency is independent
of fragment length making it ideal for use with archival DNA. Where
samples are limiting and amplification is required, this is carried
out using natural unmodified nucleotides which is then followed by
the one step ULS labeling.

     Brent Keller, acting Commercial Director for Kreatech states "Our
decision to make available arrayCGH labeling kits that offers a
choice of fluorescent dye pairs from the leading dye manufacturers
is consistent with our strategy to offer ULS technology independent
of array platform used and the labels that researchers work with. In
this way, ULS can be the ubiquitous choice of researchers for their
labeling needs, eliminating the concern over matching arrays and
labels with the offering of every manufacturer."

     Kreatech earlier this year launched a line of aRNA labeling kits
for expression arrays with dye pairs from GE Healthcare, Perkin
Elmer, Dyomics and a Biotin system for Affymetrix users.

     For more information on the ULS labeling kits visit
http://www.kreatech.com



SOURCE Kreatech Biotechnology B.V.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

http://www.milkeninstitute.org/publications/publications.taf?
function=detail&ID=454&cat=ResRep

MilkenInstitute.Org > Publications > The Greater Philadelphia Life
Sciences Cluster: An Economic and Comparative Assessment

The Greater Philadelphia Life Sciences Cluster: An Economic and
Comparative Assessment
Ross DeVol, Rob Koepp, Lorna Wallace, Armen Bedroussian and Daniela
Murphy
June 2005



Price:$ 35.00*

As you order, the number of items in your shopping cart will appear
in the upper right corner. You may make changes at checkout.


The life sciences industry is an emerging powerhouse for U.S. global
economic competitiveness in the 21st century. So which metropolitan
areas are in the lead for this important engine of economic growth?

According to this study, Boston, the San Francisco Bay Area and
Greater Philadelphia have the most dynamic life sciences clusters in
the country.

Encompassing biotechnology, pharmaceuticals, medical devices,
associated research and development activities, and supporting
infrastructure – including research universities, teaching
hospitals, medical laboratories and venture capital firms – life
sciences is one of the most knowledge-intensive and research-rich
sectors of the U.S. economy. It directly and indirectly supports
millions of jobs and pays above-average wages to life science
industry workers.

The study was sponsored by BioAdvance, PricewaterhouseCoopers,
Pennsylvania BIO and the Greater Philadelphia Chamber of Commerce's
CEO Council for Growth, which asked the Institute to undertake the
study to gauge the Greater Philadelphia region's standing compared
to the other leading life sciences clusters in the U.S.

Researchers benchmark and assess the current position of the Greater
Philadelphia life sciences sector relative to 10 other leading
centers – Greater New York, Boston, Greater Raleigh Durham,
Minneapolis, Chicago, Dallas, Greater San Francisco, Seattle,
Greater Los Angeles and San Diego – and estimate the total impact on
the region's economy by calculating the multiple ripple effects,
evaluate how it is positioned for future growth by investigating its
ongoing ability to innovate, and formulate an overall composite for
the life sciences.

The Greater Philadelphia life sciences cluster ranks among the elite
centers in the country. Its life sciences industry is a clear
potential source of comparative advantage for the region's economy
over the long term and it ranks among the largest clusters in the
country.

The study includes detailed statistics from the dozens of
measurements examined by researchers in each of the 11 clusters

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

i am pooja from India and would like to join as
project fellow in biotech.or wanna join job in research field.
i did M.Sc-biotech with first div.
kindly,help me if you can?
pooja

BIO Ventures for Global Health Announces Bill & Melinda Gates
Foundation Grant to Expand Biotech Industry's Role in Fight Against
Neglected Diseases

Four-year, $5.4 Million Grant Will Help Companies Overcome Market
and Funding Barriers


PHILADELPHIA, June 21 BIO Ventures for Global Health today announced
it will expand its efforts to enlist biotechnology companies in the
fight to improve global health, with a new $5.4 million grant from
the Bill & Melinda Gates Foundation. BVGH is a nonprofit venture
founded last year by the Biotechnology Industry Organization, with
support from the Gates Foundation and the Rockefeller Foundation.
The announcement was made at BIO 2005, the biotech industry's annual
convention.

"The biotech industry has tremendous potential for developing new
therapeutics, vaccines and diagnostics against diseases of the
developing world," said Richard Klausner, MD, executive director of
the Gates Foundation's Global Health program. "For too long,
funding, market, and information barriers have prevented biotech
companies from realizing this potential. We believe that BIO
Ventures for Global Health will provide the means to help industry
overcome some of these barriers. We congratulate BVGH in taking
leadership in helping to bring the potential of biotechnology to
improving health equity in our world."

The new grant will help BVGH launch a series of business cases to
assess and build market opportunities for neglected diseases.
Companies are deterred by an insufficient understanding of
developing world markets and many lack the capacity to generate this
knowledge on their own. To evaluate whether to invest in a
technology, they need information on potential market demand and
pathways to get products tested, licensed and distributed. BVGH will
fill that gap. The business cases, a tool used regularly by
industry, will explore new models for tapping into emerging markets.
BVGH's first business case will evaluate the market opportunity for
tuberculosis vaccines.

"This grant represents a historic shift in thinking about how to
engage the biopharma sector in addressing the unmet health needs of
people in developing countries," said Rob Chess, Chairman of
BVGH. "We understand the business of biotech and are seeking ways to
translate that knowledge into solutions that improve the lives of
individuals in the poorest regions of the world."

For markets that are too small to compete with other industry
opportunities, BVGH will pursue market incentives to enhance the
underlying market and "pull" new industry investment. Over the last
year, BVGH has reached out aggressively to biotechnology companies
and has represented the industry in talks with the World Bank and
the finance ministers of the G7 countries to design advance market
commitments to spur biotech innovation for critical products such as
AIDS and malaria vaccines.

"BVGH is uniquely placed, with access to -- and intellectual support
from -- the most innovative biopharma companies -- large and small,"
said Jim Greenwood, President of the Biotechnology Industry
Organization. "BVGH has treated global health as a business from the
outset, and funding for their efforts should have a catalytic impact
on industry's response to these immense global challenges."

Currently, less than 10 percent of health research funding is
targeted to diseases that account for 90 percent of the global
disease burden. BVGH aims to radically change that equation.

"The biopharma industry is ready and willing to tackle the tough
scientific and technical challenges in global health, but the market
has to be there," said BVGH Executive Director Wendy Taylor. "We're
creating the business roadmap -- through improved markets and
creative new business models -- that will lead industry to those
much-needed solutions."

About BIO Ventures for Global Health

BIO Ventures for Global Health (BVGH) is a global, non-profit entity
that seeks to break traditional barriers to global health product
development, bridging the gap between biotechnology's immense
promise and the enormous unmet health needs of the developing world.
By uncovering and building new market opportunities -- through
better market information, creative business models and new market
incentives -- BVGH aims to catalyze industry investment in global
health innovations to address the unmet health needs of the poorest
regions of the world. More information is online at
http://www.bvgh.org.




---------------------------------------------------------------------
-----------
Source: BIO Ventures for Global Health; Biotechnology Industry
Organization


http://www.arizonabiotech.com/
http://smsac.blogspot.com/
http://groups.yahoo.com/group/biotech-news/

Berna Biotech Enters Australia, Swiss Cooperations


Swiss biotechnology company Berna Biotech AG (BBIN.EB) Wednesday
said it entered new cooperations with Australia-based CSL Ltd
(CSL.AU) and Swiss company Apoxis.

Berna Biotech entered an exclusive commercialization and licence
agreement for Aerugen in Australia and New Zealand with CSL. Aerugen
is a vaccine for the prophylaxis of Pseudomonas aeruginosa
infections in cystic fibrosis patients and is expected to be
launched in Europe in the year 2007.

Melbourne-based CSL is a biopharmaceutical company that develops,
manufactures and markets products to treat and prevent serious human
medical conditions.

With Apoxis an agreement for clinical-grade, recombinant protein
production and supply was signed. Berna Biotech will help in the
production of Apoxis' produce recombinant MegaFasL product for phase
I clinical trials in oncology.

Apoxis develops novel therapeutic proteins able to modulate
apoptotic cell death, or cell suicide. Apoptosis plays a central
role in the regulation of cancer and autoimmune disease and its
control, through agonistic or antagonistic molecules, holds great
promise for the treatment of life-threatening diseases.

http://www.bernabiotech.com



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

FierceBiotech Honors Xencor as One of the ``Fierce 15'' Biotech
Companies of 2005

Xencor, Inc., a company engineering superior biotherapeutics using
its Protein Design Automation(R) technology, announced today that it
has been selected as one of the "Fierce 15" for 2005 by
FierceBiotech, an internationally recognized publication for the
biotech industry covering the biotechnology and pharmaceutical
markets. Xencor was chosen as one of the top emerging biotechnology
companies for the company's innovative Protein Design Automation (PDA
(R)) technologies, including Xencor's XmAb(TM) technology that
improves the potency of monoclonal antibodies.


"The beauty of Xencor's work is that it focuses on the constant
region of an antibody, redesigning a segment that helps it more
effectively attack a target cell by improving an antibody's natural
immune system recruitment," says John Carroll, of
FierceBiotech. "Like the other swiftly developing companies on this
year's Fierce 15 list, we'll be watching Xencor closely in the years
ahead."

"Xencor's PDA technology has allowed the company to generate an
outstanding roster of industrial collaborators and grow an internal
pipeline of biotherapeutics, with our lead candidate for the
treatment of rheumatoid arthritis, DN-TNF, expected to enter human
trials in 2006," said Bassil Dahiyat, President and CEO of
Xencor. "Xencor is honored to be chosen for this distinction by
FierceBiotech, a recognized leader in the industry for advancing an
understanding of biotechnology companies and the life science
community."

The Fierce 15 celebrates the spirit of being "fierce" -- championing
innovation and creativity, even in the face of intense competition.
The list of Fierce 15 companies is available in today's issue of
FierceBiotech and on the FierceBiotech Web site at
http://www.fiercebiotech.com.

About FierceBiotech

FierceBiotech, an internationally recognized email newsletter for
the biotech industry, provides more than 35,000 executives a must-
read briefing on the day's top stories in the biotech and
pharmaceutical industries. Visit http://www.fiercebiotech.com for
additional information.

About Xencor

Xencor, Inc., engineers biotherapeutics including protein
therapeutic candidates and XmAb(TM) antibody drug candidates using
its proprietary Protein Design Automation(R) technology platform.
The company is internally advancing several therapeutics against
biologically validated targets, including a protein therapeutic drug
candidate for the treatment of arthritis and other rheumatic
disorders and antibody candidates for the treatment of cancer. With
multiple partners such as industry leaders Genentech and Roche,
Xencor applies its suite of XmAb antibody Fc domains to improve
antibody drug candidates for traits such as potency, affinity, and
stability. Xencor also develops therapeutic protein variants in
collaboration with major pharmaceutical partners. For more
information, please visit www.xencor.com.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Biotech Breakthrough Will Favorably Impact the U.S. Chemical Industry

Codexis and Cargill, members of the Biotechnology Industry
Organization's (BIO) Industrial and Environmental Section, today
announced a breakthrough in developing a novel microbial process
that will convert corn sugar to a chemical intermediate. This
process is an important milestone in the development of a new
renewable chemical platform. When fully commercialized, the
industrial biotech process will convert dextrose derived from corn
to a chemical intermediate known as 3, hydroxyproprionic acid (3HP).

The new process will utilize very low-cost, clean agricultural
feedstocks instead of petroleum to produce 3HP. 3HP is a key
intermediate for several commercially important chemicals. The
chemicals that can be produced from 3HP include acrylic acid,
acrylamide and 1,3 propanediol. Acrylic acid and its derivatives are
used to create a wide range of polymer-based consumer and industrial
products, such as adhesives, paints, polishes, protective coatings,
and sealants. This new process is cheaper and more environmentally
friendly than the old process that uses petroleum as a feedstock.

"Industrial biotechnology converges seamlessly with other scientific
disciplines and is a powerful source of innovation for new products
and processes," stated Brent Erickson, executive vice president for
BIO's Industrial and Environmental Section. "The global acrylic acid
market is worth over $4 billion. This breakthrough is going to shake
up the chemical industry and it will help U.S. companies that adopt
it to be more competitive in the global marketplace."

"With natural gas and crude oil prices going through the roof, the
commercialization of this renewable chemical platform should be
great news for the chemical industry. The chemical industry needs
new feedstocks to stay competitive, and this chemical platform will
be based on corn, not foreign oil. Furthermore, the biobased economy
that is evolving is about more than just ethanol," Erickson
added. "The interface between industrial biotechnology and
agricultural production provides the ability to produce inexpensive,
natural raw materials -- such as sugars and lipids -- for
manufacturing biobased products. Sugars and lipids from agricultural
crops can be used in many products, replacing increasingly expensive
oil and natural gas, which are currently the main feedstocks of the
chemical industry," Erickson continued.

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.




---------------------------------------------------------------------
-----------
Source: Biotechnology Industry Organization

http://www.arizonabiotech.com/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://groups.yahoo.com/group/biotech-news/

Curis to Present at the Bear Stearns Boston Biotech Confab

CAMBRIDGE, Mass.
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company,
today announced that the Company will be presenting at the Bear
Stearns Boston Biotech Confab on Tuesday, June 28, at the Hyatt
Regency in Cambridge, Massachusetts.


Daniel Passeri, Curis' President and Chief Executive Officer, will
provide an overview of the status of Curis' business and
collaborations at 3:05 p.m. Eastern. There will be an audio webcast
of the presentation at:
customer.talkpoint.com/BEAR002/062805a_cy/default.asp?entity=curis
(Due to its length, this URL may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one
exists.)

The presentation will be archived shortly after the live event and
available for 30 days following the conference. The presentation
will also be available on the Investor Relations section of Curis'
website at www.curis.com.

About Curis, Inc.

Curis, Inc. is a therapeutic drug development company. The Company's
technology focus is on regulatory pathways that control repair and
regeneration. Curis' product development involves the use of
proteins or small molecules to modulate these pathways. Curis has
successfully used this technology and product development approach
to produce several promising drug product candidates in the fields
of cancer (under collaboration with Genentech, which also includes a
co-development arrangement for a basal cell carcinoma product
candidate), kidney disease (licensed to Ortho Biotech Products and
under development at Centocor, both subsidiaries of Johnson &
Johnson), neurological disorders (under collaboration with Wyeth),
hair growth, and cardiovascular disease. For more information,
please visit the Curis web site at www.curis.com.

Contacts


  Curis, Inc.
Chief Financial Officer
Michael P. Gray, 617-503-6632
or
Director, Corporate Communications
Megan E. Burling, 617-503-6658

Bristol-Myers Squibb Company Signs Manufacturing Agreement With
Celltrion
Tuesday June 21, 10:00 pm ET
- Celltrion To Produce Select Biologic Products -


PRINCETON, N.J., June 21 /PRNewswire-FirstCall/ -- Bristol-Myers
Squibb Company (NYSE: BMY - News) announced today that it has
completed an agreement with Celltrion, Inc. for Celltrion to
manufacture biologic products being developed by Bristol-Myers
Squibb. Commercial terms of the agreement were not disclosed.
ADVERTISEMENT


"A key element of our company strategy is the expansion of our
portfolio of biologic products. In support of that goal we must
continuously assess our manufacturing capabilities," said Carlo de
Notaristefani, president, Technical Operations, Bristol-Myers
Squibb. "Bristol-Myers Squibb has several biologic products in
various stages of development, including the late stage products
abatacept and belatacept. This agreement increases our biologic
manufacturing capacity to help ensure sufficient long-term supply of
our products."

The Celltrion facility, located in Incheon, South Korea, is capable
of producing multiple products, including abatacept and belatacept.
This agreement adds to Bristol-Myers Squibb's existing biologic
manufacturing capacity, which includes a biologic manufacturing
facility in Syracuse, NY owned and operated by the company and a
previously announced biologics manufacturing agreement with Lonza
Biologics PLC.

Bristol-Myers Squibb is a global pharmaceutical and related health
care products company whose mission is to extend and enhance human
life.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains certain forward-looking information
within the meaning of the Private Securities Litigation Reform Act
of 1995 regarding a product in development and the potential
efficacy of such product that involves substantial risks and
uncertainties. Such risks and uncertainties include, among other
things, the uncertainty of the success of the research and
development activities; decisions by regulatory authorities
regarding whether and when to approve any new drug application for a
product candidate that may result from the research, as well as
their decisions regarding labeling and other matters that could
affect the commercial potential of such product candidate; and
competitive developments. A further list and description of risks
and uncertainties can be found in the Bristol-Myers Squibb's Annual
Report on Form 10-K for the fiscal year ended December 31, 2004, and
in its reports on Form 10-Q and Form 8-K. The Company undertakes no
obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.




---------------------------------------------------------------------
-----------
Source: Bristol-Myers Squibb

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

Berna Biotech Announces Two New Collaborations



· with the Australian-based biopharmaceutical company CSL regarding
Aerugen for Australia and New Zealand



· with the Swiss-based biopharmaceutical company Apoxis regarding
recombinant protein production


BERNE, Switzerland, June 22, 2005--Berna Biotech Ltd (SWX: BBIN)
announced today two new collaborations:

With CSL an exclusive commercialisation and licence agreement for
AerugenÒ in Australia and New Zealand was signed. AerugenÒ is a
vaccine for the prophylaxis of Pseudomonas aeruginosa infections in
cystic fibrosis patients and is expected to be launched in Europe in
the year 2007.

CSL Limited is a global, specialty biopharmaceutical company that
develops, manufactures and markets products to treat and prevent
serious human medical conditions; Headquartered in Melbourne
Australia, the CSL Group includes CSL Bioplasma, CSL Pharmaceutical
and ZLB Behring incorporating ZLB Plasma Services.

With Apoxis an agreement for clinical-grade, recombinant protein
production and supply was signed: Berna will apply its mammalian-
cell process development expertise and state-of-the-art
manufacturing facility to the production of Apoxis' recombinant
MegaFasL product for phase I clinical trials in oncology.

Apoxis SA is a Swiss-based biopharmaceutical company. Apoxis
develops novel therapeutic proteins able to modulate apoptotic cell
death (cell suicide). Apoptosis plays a central role in the
regulation of cancer and autoimmune disease and its control, through
agonistic or antagonistic molecules, holds great promise for the
treatment of life-threatening diseases. For further information see
http://www.apoxis.com

No financial details were disclosed.

For further information:

Berna Biotech Ltd
Patrik Richard
Corporate Secretary
communications@...
Phone +41 (0) 31 980 64 91
www.bernabiotech.com

CSL Ltd
Dr Rachel David
Director, Public Affairs
rachel.david@...
Phone 0401 775 779
www.csl.com.au

Apoxis SA
Cedric Haenni
Chief Operation Officer
haenni@...
Phone: +41 (0)21 620 60 82
www.apoxis.com


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

New Study Shows Embryonic Stem Cell Lines Classified by ``MicroRNA''
Expression; Applied Biosystems TaqMan MicroRNA Assays Quantify
Minute Changes in MicroRNA Expression during Stem Cell
Differentiation

Results May Have Implications in Determining Optimal Stem Cell Lines
for Therapeutic Research

In conjunction with the International Society for Stem Cell Research
(ISSCR) Annual Meeting, Applied Biosystems Group (NYSE:ABI), an
Applera Corporation business, and the University of Colorado today
presented data using a preliminary version of Applied Biosystems
TaqMan(R) MicroRNA Assays to profile microRNA (miRNA) expression in
mouse stem cells.

The collaborative research study shows embryonic stem cells can be
classified according to miRNA expression profiles, potentially
having implications in determining optimal stem cell lines. Using
TaqMan miRNA assays, researchers were able to accurately determine
expression levels across a large panel of miRNAs and reveal precise
changes in individual miRNA expression during stem cell
differentiation. The assays discriminated between miRNAs differing
by as little as a single nucleotide and between mature miRNAs and
their precursors, even in single cells.

Increasing evidence indicates miRNAs, a recently discovered class of
small RNA molecules, play a powerful gene regulatory role in cell
differentiation and developmental biology, cancer, and other
diseases.

"The different microRNA expression profiles in embryonic stem cells
suggest some embryonic cell cultures may contain variable
subpopulations of spontaneously differentiated cells," said William
M. Strauss, Ph.D., Assistant Research Professor, Department of
Molecular, Chemical and Developmental Biology (MCDB), University of
Colorado, Boulder. "Our newly identified microRNAs could one day be
used as molecular markers for monitoring differentiation within
embryonic stem cell lines."

Researchers examined the expression levels of 252 mouse and human
miRNAs in four mouse embryonic stem cell lines, differentiated
embryoid bodies, and six mouse tissues. Preliminary results found
embryonic stem cells could be accurately classified and
differentiated from embryoid bodies and adult tissue using their
distinct miRNA expression signatures.

"We are excited about the potential of our novel TaqMan(R) MicroRNA
Assays to provide further insights about the role of miRNAs in cell
differentiation," said Dennis Gilbert, Ph.D., Chief Scientific
Officer, Applied Biosystems. "This is the first time a technology
has been able to quantify miRNAs easily and accurately using
starting samples as small as a single cell. These findings may hold
promise for stem cell researchers as they identify optimal cell
lines for use in therapeutic research."

In addition, data showed a total of 55 percent (138) of miRNAs
studied were up-regulated by more than a fold, while only one
percent (3) were down-regulated during the development of embryonic
stem cells into embryoid bodies, suggesting miRNA expression levels
globally increase during embryonic stem cell differentiation and may
play an important role in activating lineage-specific genes.

Applied Biosystems TaqMan(R) MicroRNA Assays distinguish between
mature miRNAs and their precursor form by using a proprietary stem-
loop technology for reverse transcription (RT) of the mature miRNA,
followed by quantitative real-time PCR. Applied Biosystems currently
has a large set of the miRNA assays in development and plans to
commercialize its miRNA assay technology based on TaqMan(R) 5'
nuclease chemistry for real-time PCR.

The poster (#53), titled "TaqMan-Based MiRNA Profiles Classify
Embryonic Stem Cells (ES) and Differentiated Cells," will be
presented at ISSCR today, June 23, from 5:30 to 7 p.m. and during an
ISSCR tutorial, titled "Real-Time PCR Applications for Stem Cell
Research," from 7 to 8 p.m. To register for the tutorial go to
http://info.appliedbiosystems.com/isscr. A copy of the poster can be
downloaded at http://miRNA.appliedbiosystems.com.

About University of Colorado

The University of Colorado is a three-campus system with campuses in
Boulder and Colorado Springs, and the recently consolidated Denver
and Health Sciences Center campuses located in Denver and at the
former Fitzsimons Army Base in Aurora. For further information,
please contact Michele McKinney in the CU System Office of
Institutional Relations at (303) 492-6206.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied
Biosystems Group serves the life science industry and research
community by developing and marketing instrument-based systems,
consumables, software, and services. Customers use these tools to
analyze nucleic acids (DNA and RNA), small molecules, and proteins
to make scientific discoveries, develop new pharmaceuticals, and
conduct standardized testing. Applied Biosystems is headquartered in
Foster City, CA, and reported sales of $1.7 billion during fiscal
2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in
the discovery and development of targeted therapeutics for cancer,
autoimmune and inflammatory diseases. Celera Genomics is leveraging
its proteomic, bioinformatic, and genomic capabilities to identify
and validate drug targets, and to discover and develop small
molecule therapeutics. It is also seeking to advance therapeutic
antibody and selected small molecule drug programs in collaboration
with global technology and market leaders. Celera Diagnostics, a
50/50 joint venture between Applied Biosystems and Celera Genomics,
is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation,
including reports and other information filed by the company with
the Securities and Exchange Commission, is available at
http://www.applera.com, or by telephoning 800.762.6923. Information
about Applied Biosystems is available at www.appliedbiosystems.com.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These
may be identified by the use of forward-looking words or phrases
such as "plan," "expect," and "should," among others. These forward-
looking statements are based on Applera Corporation's current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In
order to comply with the terms of the safe harbor, Applera
Corporation notes that a variety of factors could cause actual
results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements. These factors include but are not limited to (1) rapidly
changing technology and dependence on the development and customer
acceptance of new products; (2) sales dependent on customers'
capital spending policies and government-sponsored research; (3)
Applied Biosystems' dependence on the operation of computer
hardware, software, and Internet applications and related
technology; (4) unproven use of genomics information to develop or
commercialize products; and (5) other factors that might be
described from time to time in Applera Corporation's filings with
the Securities and Exchange Commission. All information in this
press release is as of the date of the release, and Applera does not
undertake any duty to update this information, including any forward-
looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

The PCR process and the 5' nuclease process are covered by patents
owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd.

Copyright(C) 2005. Applera Corporation. All rights reserved. Applied
Biosystems and Celera are registered trademarks and Applera is a
trademark of Applera Corporation or its subsidiaries in the U.S.
and/or certain other countries. TaqMan is a registered trademark of
Roche Molecular systems, Inc.

Contacts


  Applied Biosystems
Sophie Patel, 650-554-2732 (Media)
sophia.patel@...
Peter Dworkin, 650-554-2479 (Investors)
dworkipg@...
European Media and Investors
David Speechly, Ph.D., (+) 44.162.273.9150
speechdp@...






http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

Combating Cancer with Gene Therapy

   Frost & Sullivan to Host Interactive Quarterly Analyst Briefing on
Gene Therapy in the Cancer Treatment Markets on Tuesday, June 28,
2005.

The Technical Insights group at Frost & Sullivan is pleased to
announce its exclusive 2005 Quarterly Industry Analyst Briefing on
gene therapy in the cancer treatment market to be held on Tuesday,
June 28, 2005 at 1:00pm EDT / 12:00pm CDT.

The briefing will provide manufacturers, researchers in
pharmaceutical and biotech companies and other industry participants
with an overview of the current state of gene-therapy technologies
focused on the treatment of cancer. The briefing will discuss
various types of technologies under development for improved gene
delivery and different gene therapy approaches for selective killing
of tumor cells. Highlights of the briefing include technology
overview, industry trends, key drivers, barriers to
commercialization and an insight into important clinical trails.

"Cancer continues to be the primary target for gene therapy with
more than 2.5 million new cases of cancer diagnosed each year
worldwide. Today an increased knowledge about the role of genes in
cancer has led to the development of novel cancer therapies," says
Frost & Sullivan Technical Insights Research Analyst, A.N. Aditya.

The presentation will discuss some of the latest happenings and
technology trends in this sector. Government, public and private
initiatives will also be discussed. This free teleconference will
cover the overview of the gene therapy in the cancer treatment
market, the future outlook of emerging technologies and an
interactive question and answer session.

Those interested in participating in this exclusive analyst briefing
should send an email to Danielle White, dwhite@..., with the
following information for registration: full Name, company name,
title, telephone number, fax number, city, state, address, and email
address. Upon receipt of the above information, a confirmation/pass
code for the live briefing will be emailed to you.

Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services, and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit http://www.frost.com.

Contacts


  Frost & Sullivan, San Antonio
Corporate Communications - Healthcare
Danielle White, 210-247-2403
dwhite@...
http://www.frost.com



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/

Australia Recognized Globally as Stem Cell Research Hub
Wednesday June 22, 8:08 am ET
Government funding and supportive legislation backs nation's stem
cell research excellence



Australia, known globally for its biotech R&D capabilities and
strengths in human therapeutics, agribiotech, diagnostics, medical
devices and biodiscovery, will has some of its best in stem cell
research capabilities on show at BIO 2005.
While human cloning is currently prohibited in Australia, embryonic
and adult stem cell research is allowed. Australia continues to lead
the world in stem cell research with innovative programs now
underway to develop potential treatments for diabetes, Parkinson's
and heart disease.

Studies currently underway at Australia's government backed
Australian Stem Cell Centre [ASCC], and some of its collaborative
partner institutions, include development of potential therapies for:


      * Congestive cardiac failure
      * Hematological disorders
      * Respiratory diseases
      * Disease and injury of the kidney

The ASCC announced at BIO 2005 that, as testament to the nation's
standing in the stem cell arena, the International Society for Stem
Cell Research's annual meeting will, for the first time meet outside
North America -- in the Australian city of Cairns in the State of
Queensland, in 2007.

Dr Anna Lavelle, the newly appointed Chief Executive Officer of
AusBiotech, Australia's peak biotech industry organization, said
Australia has been actively involved in R&D in this area.

In 1980 the first IVF birth in Australia was reported. In 1983
Australia announced the world's first egg donor baby and the
development of embryo freezing technology that resulted in the first
frozen embryo baby.

"Since then Australian IVF and stem cell research teams have clocked
advances in this sector with world-class research and solid
government backing aimed at creating therapies for real health
issues facing Australians -- and the world," said Dr Lavelle.

To make an appointment with members of the Australian delegation
please go to Austrade's online diary and select the Business
Matching service where your request will be confirmed within 24
hours: www.austrade.gov.au/bio2005/.

For a listing of the 63 Australian exhibitors at BIO2005, please
visit the Australian Exhibitor section of Invest Australia's BIO
2005 website at www.investaustralia.gov.au/biotech/bio2005 .

About AusBiotech -- www.ausbiotech.org

AusBiotech is Australia's biotechnology industry organization, which
represents over 2,400 members, covering the human health,
agricultural, medical device, environmental and industrial sectors
in biotechnology.

AusBiotech is dedicated to the development, growth and prosperity of
the Australian biotechnology sector, by providing initiatives to
drive sustainability and growth, outreach and access to markets, and
representation and support for members nationally and around the
world.

AusBiotech has representation in each Australian State and provides
the foundation to bring together all the relevant players to
facilitate the commercialization of Australian bioscience in the
national and international marketplaces. The structure is a not-for-
profit limited guarantee company managed by a Board elected by
members, under a constitution that is available on request from
National Office.

AusBiotech's membership base includes biotechnology companies,
ranging from start-ups to mature multinationals, research institutes
and universities, specialist service professionals, corporate,
institutional, individual and student members from Australia and
globally.

About Invest Australia -- www.investaustralia.gov.au/biotech

Invest Australia is Australia's national inward investment agency,
set up by the Australian Federal Government in 1997, to attract
productive foreign direct investment into Australia to support
sustainable industry growth and development. Invest Australia has
investment advisory specialists in 11 locations around the world,
including San Francisco and New York, to provide investors with on-
the-ground support and investment advice, including free and
confidential advice to firms to help find the right business
partners and identify commercial opportunities. In the past two
financial years, to June 2004, Invest Australia has played a role in
attracting 105 projects worth US$11.1 billion, involving 9,470 jobs.

About Austrade -- www.austrade.gov.au

The Australian Trade Commission, Austrade, is the Federal Government
agency that helps Australian companies win overseas business for
their products and service by reducing the time, cost and risk
involved in selecting and developing international markets.
Biotechnology is as a major source of growth for Australian industry
and as such Austrade has established a specialist Biotech team.

Austrade, with seven offices in the US, can assist international
biotechnology companies to partner with Australia's leading
biotechnology companies and clusters of excellence.

About the Australian Stem Cell Centre -- www.stemcellcentre.edu.au

The Australian Stem Cell Centre is a major Australian collaborative
initiative uniting many of the country's leading academic
researchers with the biotechnology industry to develop innovative
therapeutic products to treat blood and heart diseases.

The Centre will build on Australia's existing expertise in stem cell
and related platform technologies to lay the foundations for
delivering stem cell therapies.




---------------------------------------------------------------------
-----------
Source: AusBiotech


http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

Generex Biotechnology Begins Research Collaboration on Novel Allergy
Therapy With Major European Company

Stallergenes, a Principal European Allergy Firm Near Paris, Tests
Novel Approach to Immunotherapy of Allergy and Asthma Designed by
Antigen Express



Generex Biotechnology Corporation (Nasdaq: GNBT - News) today
announced that a Research Collaboration Agreement has been signed by
its subsidiary Antigen Express, Inc. with Stallergenes, S.A. a major
European firm in immunological treatments for allergy and asthma.

The studies are to design and test Ii-Key/allergen epitope hybrid
peptides to create a novel approach for the control of both
dangerous forms of asthma and functionally disabling allergic
reactions. A large number of individuals in both North America and
Europe suffer from various forms of allergic responses. These range
from allergic rhinitis to cat dander, to ragweed hayfever, to
potentially fatal asthmatic attacks from bee sting or peanut
allergens.

Antigen Express scientists have discovered that a segment of the
immunoregulatory protein called Ii, acts on the HLA-DR molecules,
which present antigenic peptide epitopes of allergens to T
regulatory lymphocytes. By coupling this Ii-Key peptide covalently
to the antigenic epitope peptides, the potency of the HLA-DR
presented epitope is increased about 200 times in cell culture
experiments and about 8 to 10 times after injecting animals.

Allergists have been seeking a method to stimulate T helper cells in
a manner that directs the immune response away from the allergic
pattern. Allergy symptoms arise when a T helper cell type 2 (TH2)
response occurs to an environmental antigen, stimulating production
of immunoglobulin E (IgE). When IgE is crosslinked by recognition of
an allergen protein, on the surface of mast cells and basophils,
histamine and other mediators of allergy are released. A wide range
of responses can be found ranging from local redness and swelling in
the skin, itchy nose, ears, roof of mouth, watery eyes and sneezing,
to severe bronchoconstriction requiring powerful medicines and
potentially intubation and respiratory support.

Antigen Express scientists have found that their established
approach to stimulating responses to cancer and infectious disease
antigens stimulates a strong TH1 response, away from a TH2 response.
That is exactly the pattern sought in research studies to tune down
allergic reactions. This method of treatment goes directly to the
cause of the allergic response, rather than just treatment of
symptoms.

"Since my days in the Allergy Clinic of the Bethesda Naval Hospital,
trying to help patients with moderate to severe forms of allergy and
asthma, I have followed the scientific and clinical literature
toward making some better product," said Robert Humphreys, M.D.,
Ph.D., the Chief Scientific Officer of Antigen Express. He feels now
that he might just have that better product to control allergic
reactions. Nevertheless, "A lot of work lies ahead, in collaboration
with skilled researchers and clinicians working in allergy."

In collaboration with Dr. Philippe Moingeon, Director of Research
and Development at Stallergenes, Dr. Humphreys has designed a series
of

Ii-Key/allergic epitope hybrid peptides for assays in France, using
both lymphocytes from allergic patients and in mouse animal models.
Dr. Moingeon said, "Bob Humphreys has developed a novel approach to
controlling allergy. We seek to test it further in the laboratory,
to see if basic biological mechanisms support further work toward
clinical trials. Potential advantages lie in the use of peptide
fragments of the allergen, not recognized by IgE, and in the
enhanced potency of the epitope so that therapy can be at very small
doses."

About Generex

Generex is engaged in the research and development of drug delivery
systems and technologies. Generex has developed a proprietary
platform technology for the delivery of drugs into the human body
through the oral cavity (with no deposit in the lungs). The
Company's proprietary liquid formulations allow drugs typically
administered by injection to be absorbed into the body by the lining
of the inner mouth using the Company's proprietary RapidMist(TM)
device. The Company's flagship product, oral insulin (Oral- lyn
(TM)), which has been approved for commercial sale in Ecuador for
the treatment of patients with Type-1 and Type-2 diabetes, is in
various stages of clinical trials around the world. Generex acquired
Antigen Express in August, 2003. The core platform technologies of
Antigen Express comprise immunotherapeutics for the treatment of
malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex Web site at
http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from
time to time by Generex representatives concerning the same subject
matter may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements can be identified by introductory words such
as "expects," "plans," "intends," "believes," "will," "estimates," "f
orecasts," "projects" or words of similar meaning, and by the fact
that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and
approvals, and similar operating matters. Many factors may cause
actual results to differ from forward-looking statements, including
inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward- looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex claims the protection of
the safe harbor for forward-looking statements that is contained in
the Private Securities Litigation Reform Act.




---------------------------------------------------------------------
-----------
Source: Generex Biotechnology Corporation

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.azhttp.com/
http://www.arizonaentrepreneurs.com/

Osiris Raises $50 Million to Commercialize First Stem Cell Products;
Proceeds will advance three promising treatments currently in human
trials


Osiris Therapeutics, Inc. announces that it has finalized a $50
million aggregate private investment round through equity and
convertible debt. The financing will fund the company's three
ongoing clinical trial programs using their proprietary adult stem
cell technology platform. The round was arranged by Swiss investment
firm Friedli Corporate Finance, Inc.


"With this successful funding round and the progress being made in
the three clinical trials, Osiris continues to demonstrate its
ability to execute its commercialization plan," said Chairman of the
Board, Peter Friedli. Mr. Friedli is one of the founders of Osiris
and was instrumental in arranging the current financing.

"This level of support signifies the confidence our investors have
in Osiris to be the first company to bring a stem cell therapy to
market," said C. Randal Mills, PhD, President and CEO of Osiris. "As
always, we are pleased with the unwavering support of our loyal
investors, and we welcome the new investors who participated in the
round. The proceeds will be used to aggressively advance our product
commercialization plans and bring these revolutionary treatments to
patients in need."

The first product, Prochymal(TM), now in Phase II clinical trials,
is a formulation of adult stem cells to treat Graft versus Host
Disease (GvHD), a life threatening disease afflicting leukemia
patients who have received a bone marrow transplant. Osiris has
recently enrolled several prominent cancer centers in the trial
including the M.D. Anderson Cancer Center in Houston, Texas, one of
the world's leading bone marrow transplant facilities. "We are
hopeful that this therapy may be a viable treatment option for
patients suffering from this direct complication of
transplantation," said Partow Kebriaei, MD, Assistant Professor,
Blood and Marrow Transplantation at M.D. Anderson. "The treatments
available to us currently for Gastrointestinal GvHD are marginally
effective at best, which makes Prochymal a potentially significant
breakthrough."

The second product, Provacel(TM), a formulation of stem cells to
repair damaged heart tissue following heart attack, is enrolling
patients in a Phase I clinical trial. In preclinical studies,
Provacel reversed the damage caused by a heart attack and
significantly improved cardiac function. "This is a landmark study
that could ultimately benefit hundreds of thousands of patients a
year" said Nabil Dib, MD, Chief of Cardiovascular Research at the
Arizona Heart Institute. "The aim is to develop a stem cell product
that will repair the damage caused by a heart attack and prevent the
progression to heart failure."

Most recently, Osiris won approval from FDA to begin a Phase I/II
study for its third product, Chondrogen(TM), an injection of stem
cells formulated to repair damaged tissue in the knee joint and
prevent the progression of arthritis. Chondrogen, in development at
Osiris since 1999, has shown encouraging preclinical results that
served as the basis for FDA's decision. "The product has undergone
rigorous preclinical testing over the past six years and has shown
the ability to regrow functional meniscal tissue in as little as six
weeks," said C. Thomas Vangsness Jr., MD, Professor of Orthopedic
Surgery and Chief of Sports Medicine at the University of Southern
California's Keck School of Medicine. "More importantly, the product
prevented the progression of osteoarthritis in the knee."

Further portions of the proceeds will fund the continued enrichment
of the company's product pipeline and expand the company's extensive
intellectual property portfolio. The company currently holds more
than one hundred issued domestic and foreign patents, with over a
hundred more in various stages of approval. "Maintaining our current
patent portfolio and seeing our applications through to patent
grants will further solidify our already dominant intellectual
property position," said Cary J. Claiborne, Osiris' CFO. "This will
be especially critical as we begin to commercialize our stem cell
products and assert our considerable intellectual property rights."

About Osiris Therapeutics

Osiris Therapeutics, Inc. is the leader in adult stem cell therapy.
The stem cells produced by Osiris are obtained from adult volunteer
donors, avoiding the technical problems and controversy surrounding
other stem cell technologies. Using proprietary methods, these cells
are grown in culture to very high numbers, allowing a single donor's
cells to treat thousands of patients. These cells are universal in
that they can be used in patients unrelated to the donor, without
rejection, eliminating the need for donor matching and recipient
immune suppression. Once transplanted, the cells promote healing of
damaged or diseased tissues.

About Friedli Corporate Finance

Friedli Corporate Finance was founded by Peter Friedli in 1986 and
is one of the leading Swiss venture capital firms. Since its
inception, Friedli Corporate Finance has invested in over 170
biotechnology and technology companies, primarily based in the US.
Friedli Corporate Finance manages several investment companies for
pension funds, banks and large corporations in Switzerland. Peter
Friedli is also the manager of New Venturetec, a public investment
company listed on the Swiss exchange. www.newventuretec.com

For information about Osiris and our ongoing clinical trials, visit
our website at www.OsirisTx.com.



http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

TGen Awarded $7.1 Million to Accelerate Brain Disease Research


10,000 investigators now have access to the latest genetic scanning
technologies

June 17, 2005

The Translational Genomics Research Institute (TGen) today announced
the receipt of a $7.1 million grant from the National Institutes of
Health (NIH) to continue a project designed to uncover the genetic
causes of neurological and mental health disorders using
sophisticated genetic scanning technologies. This award is part of a
greater $25 million grant that TGen will share with three other
microarray centers that are part of the NIH Neuroscience Microarray
Consortium supported by the NIH Neuroscience Blueprint
(neuroscienceblueprint.nih.gov).
The Microarray Consortium was initially funded in 2002 by the
National Institute of Neurological Disorders and Stroke (NINDS;
www.ninds.nih.gov) and the National Institute of Mental Health
(NIMH; www.nimh.nih.gov). The new award is supported by these two
institutes as well as the thirteen other NIH Neuroscience Blueprint
institutes. The consortium combines technology resources from TGen,
Duke University in Durham, NC, and the University of California in
Los Angeles. Because of the consortium's success and an expanding
need for consortium services in neuroscience, a fourth research
center, Yale University in New Haven, Connecticut, will be added to
the program in June.

About 10,000 investigators from the 15 different NIH institutes that
are part of the NIH Neuroscience Blueprint will have access to the
technology and expertise within the consortium. These investigators
will be able to further their research through the use of microarray
technology used for scanning through the entire human genome (3
billion letters) and all of the genes for which it encodes (30,000-
40,000 genes).

"The application of the newest and most sophisticated genome
scanning technologies will allow us to unlock the mysteries of how
the brain functions normally, as well as what causes common human
disorders like Alzheimer's disease, multiple sclerosis, and others,"
said Dr. Dietrich A. Stephan, Director of the Neurogenomics Division
at the Translational Genomics Research Institute.

Genomic scanning technologies make use of the human genome sequence
to visualize how gene flavors or aberrant amounts of genes can cause
human disease. The consortium centers specialize in technologies
which provide information about the genes turned on or off in the
diseased tissues being studied. Scientists use these microarray
technologies to compare genetic patterns between an individual with
a disease and an unaffected person. Using this information,
investigators can identify the root causes responsible for certain
disorders so that diagnostics and treatments can be developed that
have a direct impact on the disease mechanisms.

The Microarray Consortium initially received $9 million from the NIH
from June 2002 to June 2005, and the new funding will be
approximately $25 million over the next five years.

"It is exciting to have the microarray consortium expanded in
capacity and expertise to serve the entire community of
neuroscientists funded by NIH institutes. The application of genomic
technologies in neuroscience is an important step in the development
of future therapies for diseases and disorders of the nervous
system," said Dr. Thomas Miller, Program Director of Extramural
Research Programs at the NINDS.

The consortium worked with 5 AM solutions, a software development
company in Phoenix, to create a central database for data generated
by the consortium. These data are freely available so the entire
scientific community can benefit from this publicly funded endeavor.

The Neuroscience Blueprint institutes are components of the National
Institutes of Health in Bethesda, Maryland and are the nation's
primary supporters of basic and applied biomedical research on the
brain and nervous system. Additional information about the NIH
Neuroscience Microarray Consortium can be accessed at
arrayconsortium.tgen.org.


# # #

About TGen The mission of the Translational Genomics Research
Institute (TGen) is to make and translate genomic discoveries into
advances in human health. Translational genomics research is a
relatively new field employing innovative advances arising from the
Human Genome Project and applying them to the development of
diagnostics, prognostics and therapies for cancer, neurological
disorders, diabetes and other complex diseases. TGen is focused on
personalized medicine and plans to accomplish its goals through
robust and disease-focused research programs and its state-of-the-
art bioinformatics and computational biology facilities.

About Duke The consortium's site at Duke University will operate in
concert with the Institute for Genome Sciences and Policy (IGSP).
The IGSP, established in 2000 with $200 million in institutional
funds, represents Duke University's comprehensive response to the
broad challenges of the genomic revolution. IGSP activities are
organized through five research centers: the Center for Genome
Technology, the Center for Human Genetics, the Center for Human
Disease Models, the Center for Bioinformatics and Computational
Biology and the Center for Genome Ethics, Law and Policy.

About UCLA The UCLA Department of Human Genetics provides a world-
class research and teaching focal point for campus-wide activities
in human genetics and gene therapy. Hailing from the School of
Medicine and the College of Letters and Science, the department's
diverse faculty is housed in the Gonda Research Center, which offers
specialized core laboratories for sequencing and genotyping, array
technology, FISH techniques and bioinformatics.

About Yale The scientific interests of the faculty at Yale represent
the full range of the broad and rapidly growing field of
neuroscience. Leaders in areas ranging from the genetic and
structural analysis of single member channels to the functional
characterization of the neocortex are represented among this group
of outstanding scientists. The interdisciplinary research programs
of Yale neuroscience faculty are central to Yale's Interdepartmental
Neuroscience Program (INP). This unique, broad-based training
program can best be described as a "department without walls," with
the primary purpose of providing students with a maximum of
diversity and depth in the most important areas of neuroscience
research. The neuroscience faculty members at Yale command more than
half of the University's biomedical research budget and occupy more
than 60,000 square feet of well-equipped laboratory space.

About 5 AM Solutions 5AM provides software solutions and technology
services for the biomedical research industry. Life science
organizations who view data organization, workflow optimization,
analysis and data mining, and geographically independent
collaboration as critical to their success are our target customers.
Our web-based, interoperable solutions access Laboratory Information
Management Systems (LIMS), support HIPAA guidelines and enforce 21
CFR 11-compliance, while granting insight into the complex data
produced by the "omic" revolution represent the core of our
expertise. We share a common passion to advance medicine and science
through our contribution of state-of-the-art software development.
www.5amsolutions.com





http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

UCLA awarded more than $6 million for biodefense and infectious
disease research

UCLA has been awarded more than $6 million over four years by the
National Institute of Allergy and Infectious Diseases to support
research for countering threats from bioterrorism agents and
infectious diseases. UCLA will be a major component of the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases
Research, a consortium of more than a dozen universities and
research institutes in California, Arizona, Nevada and Hawaii.

"Our hope is to increase fundamental knowledge on bacterial and
viral pathogens and help mitigate the bioterrorism threat," said
Jeffery F. Miller, professor and chair of microbiology, immunology
and molecular genetics at UCLA, and the center's associate director
for basic research.

Miller's laboratory will focus on bacterial pathogens and will study
an environmental organism that causes pneumonia and septicemia, and
is a potential bioterror threat. Numerous safety precautions will be
in effect, as required under federal regulations. The researchers
will work with the organism under tightly controlled conditions,
with high security and extensive oversight by the university and
federal agencies.

"This bacterium has a large genome and is largely unexplored," said
Miller, who holds UCLA's M. Philip Davis Chair in Microbiology and
Immunology. "We will work to learn the fundamental mechanisms of its
cell biology and how it causes disease. It enters cells and injects
proteins into cells using a molecular syringe."

"Our center will bring together some of the country's best basic
scientists and engineers for the common goal of preventing illness
by developing more accurate tests to detect infections and new
vaccines to protect people," said Alan Barbour, professor of
medicine and microbiology at the University of California, Irvine,
who will serve as director of the new center. Barbour is
internationally known as a co-discoverer of the bacterium that
causes Lyme disease; he also identified the protein that became an
approved vaccine against the disease.

While the center's goals include scientific applications to detect,
prevent and treat diseases and bio-agents -- including developing
vaccines -- Miller and Barbour also emphasized the importance of
basic scientific research in providing the foundation for creating a
defense against diseases and potential bioterrorism agents.

"Basic research is essential, and provides a foundation for future
applications," said Miller, a member of both UCLA's David Geffen
School of Medicine and the UCLA College. "We will study the
fundamental mechanisms of how bacterial pathogens work and cause
disease."

Miller noted that the discovery of restriction enzymes, a
fundamental tool for pharmaceutical and biotechnology companies, was
the result of pure intellectual curiosity.

"Restriction enzymes were discovered years ago not by biochemists or
geneticists looking for something practical, but because a bacterial
virus would infect one strain of E. coli, but not another; the
strain the virus would not infect expressed these enzymes that would
chop apart the bacterial virus' DNA. The researchers who made this
discovery had no immediate practical applications in mind, and yet
what came from that discovery is an indispensable tool in the
pharmaceutical and biotechnology industry.

"In addition, knowledge of the genomes of bacterial pathogens
required many years of research on model organisms such as E. coli,"
he added. "There are many such examples of the essential role basic
science has played in leading to essential medical applications."

Overall, the National Institute of Allergy and Infectious Diseases
has awarded $40 million over four years to establish the Pacific?
Southwest Center for Biodefense and Emerging Infectious Diseases
Research, which will be based at the University of California,
Irvine. The institute is part of the National Institutes of Health.

The center is one of only 10 federally funded regional centers
dedicated to research for countering threats from bioterrorism
agents and infectious diseases. Its mission will be to bolster basic
biomedical research into bioterrorism agents, such as those that
cause anthrax and botulism, and naturally occurring infectious
diseases, including West Nile virus, hantavirus and dengue, which
affect increasing numbers of people worldwide. It also will provide
scientific support, expertise and facilities in response to a
national emergency, such as a terrorist attack or an epidemic of a
new infectious disease, like the SARS virus.

The center also will create a clinical trials unit for evaluating
new vaccines. In addition, the center will support a detailed
analysis of proteins and DNA that are key to understanding
infectious diseases and bioterrorism agents, and lead efforts to
apply recent computer and engineering advances toward improving
infection detection as well as outbreak management.

In addition to Miller, researchers at UCLA who will receive funding
from the institute are Marcus Horwitz, professor of medicine and
microbiology, immunology and molecular genetics; Yong Chen,
professor of mechanical and aerospace engineering; Adrian Casillas,
assistant professor of medicine; Joel Ward, professor of pediatrics
at the Harbor-UCLA Medical Center; Hartmuth Kolb, associate
professor of molecular and medical pharmacology; and Ronald Stevens,
professor of microbiology, immunology and molecular genetics.

The center also will consist of researchers from the University of
California, Irvine; the University of California, Davis; the
University of California, Berkeley; the University of California,
Santa Barbara; the University of Southern California; the California
Institute of Technology; the Scripps Research Institute in La Jolla;
the University of Hawaii; Stanford University; Northern Arizona
University; the University of Arizona; the Desert Research Institute
in Nevada; the California Department of Health Services; and
Lawrence Livermore National Laboratory. The center will sponsor 30
research projects involving 130 researchers, post-docs, students,
and technical and support staff.

The other Regional Centers of Excellence for Biodefense and Emerging
Infectious Diseases are based in the states of Colorado, Washington,
Texas, New York, Massachusetts, Illinois, Missouri, Maryland and
North Carolina.

For more information about the Regional Centers of Excellence for
Biodefense and Emerging Infectious Diseases research, see
niaid.nih.gov/Biodefense/Research/rce.htm.

Contact: Stuart Wolpert
stuartw@...
310-206-0511
University of California - Los Angeles
www.healthcare.ucla.edu/news

Biotech Question of the Week: Got Space?

Postcard Campaign Seeking to Find Lab Space for Startups
By MARION WEBB

San Diego Business Journal Staff

Hundreds of San Diego-based biotechnologies will receive postcards
this week with an unusual proposition: Got space?

The Burnham Life Sciences Group, a specialty arm of San Diego-based
Burnham Real Estate, will drop some 700 postcards in the mail
encouraging local companies to lease access or temporary laboratory
space to fledgling companies having a tough time getting started.

"The space requirements for young biotech companies are challenging
in that they need facilities that can accommodate their research,
but generally at a size that is too small to be listed," said Brent
Jacobs, senior vice president of Burnham's Life Sciences Group. "Of
the 15 million square feet of lab space in San Diego County, nearly
all of the available space is 10,000 square feet or larger — far
more than the 1,000 to 3,000 square feet of wet lab space typically
required by startup companies."

Greg Bisconti, a partner with Burnham's Life Sciences Group, said
few landlords are willing to sign month-to-month, six-month or 12-
month leases that startups on tight budgets and risky scientific
projects can afford to sign.


http://www.sdbj.com/article.asp?aID=60162971.2745761.1160926.8983597.86472502.12\
0&aID2=89293



http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Asian `biotech hotbeds' must develop USP: E&Y report
P.T. Jyothi Datta




Mumbai , June 25

IT may still puzzle analysts why biotechnology is trusted when used
in medicine, but viewed with suspicion when used in agriculture. But
be it medicine or agriculture, Japan, China and India are the
emerging "biotech hotbeds," says an Ernst and Young (E&Y) report,
released recently at Bio 2005 in Philadelphia.

Nevertheless, "each country has to have its USP (unique selling
proposition), otherwise me-too products will be developed. And the
USP has to be matched with the bio-diversity of each country," says
E&Y's Mr Utkarsh Palnitkar, who presented the report at Bio 2005.

India's strengths are in processing, fermentation, informatics and
its vaccine manufacturing capacity. By 2010, the country will be the
largest manufacturer of vaccines in the world, Mr Palniktar told
Business Line. Also, in terms of the neglected diseases seen in
Africa, South-America and India — it makes sense to research
diseases in India, he said.

China's strengths are in bio-processing, and Korea has made strides
in stem-cell research.

In Korea, the legislation has moved in tandem with therapeutic
cloning and, as a result, companies such as LG and Samsung have
become large filers of patents, said Mr Palnitkar.

Singapore has the regulatory environment and infrastructure in
place, but it has to look outwards for people to man these, he said.

The support of the governments in India, Singapore, China and Korea,
in terms of infrastructure and policy, has given an impetus to the
biotech segment in these regions, said Mr Palnitkar, Health Sciences
leader with E&Y in India.




http://www.thehindubusinessline.com/2005/06/26/stories/2005062601390500.htm

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

BIO 2006

http://www.bio.org/events/2006/



http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

Genome study of beneficial microbe may help boost plant health

ROCKVILLE, Md - In a study expected to greatly benefit crop plants,
scientists have deciphered the genome of a root- and seed-dwelling
bacterium that protects plants from diseases.

The research provides clues to better explain how the helpful
microbe, Pseudomonas fluorescens Pf-5, naturally safeguards roots
and seeds from infection by harmful microbes that cause plant
diseases. The genome paper will be published in Nature Biotechnology
and was scheduled to be posted online on June 26.

"The genome sequence has helped us identify new chemical pathways
that the microbe apparently uses to create what are known
as 'secondary metabolites' – possibly including new antibiotic
compounds," says Ian Paulsen. He led the sequencing at The Institute
for Genomic Research (TIGR), Rockville, Md., and is the study's
first author.

The use of naturally-occurring, beneficial microbes such as P.
fluorescens to control plant pathogens is called "biological
control." That method is gaining momentum as a way to grow healthy
plants without using synthetic fungicides. In all, about three dozen
beneficial microbes are currently used as an environmentally-
friendly way to fight plant diseases.

Joyce E. Loper, senior author of the genome paper and an expert on
P. fluorescens Pf-5, predicts that the new genomic data will help
scientists more quickly develop new ways to boost the effectiveness
of beneficial microbes in fighting plant diseases.

"This genomic sequence reveals previously unknown traits of P.
fluorescens that increase its potential for biological control,"
says Loper. She is a plant pathologist with USDA's Agricultural
Research Service (ARS) and is based at Oregon State University,
Corvallis. The P. fluorescens genome was sequenced at TIGR and
analyzed by scientists there and at ARS and Oregon State University,
with contributions by researchers at Rutgers, Washington State
University and the University of Arizona. The project was funded by
a grant from the USDA's Cooperative State Research, Education and
Extension Service.

The article in Nature Biotechnology presents the first complete
genome sequence of a biological control agent for combating plant
diseases.

P. fluorescens Pf-5 was discovered two decades ago by Charles R.
Howell, a plant pathologist with the ARS in Texas, who showed that
the microbe suppressed two major cotton diseases. Since then, plant
pathologists around the world have used this strain as a laboratory
model to study beneficial microbes.

Paulsen says the P. fluorescens project also pioneered a new
methodology. This novel approach relies on the analysis of repeated
regions of the DNA sequence to help identify segments of the genome
that appear to have been transferred from other microbes or viruses,
known as phages, that infect bacteria.

Says Paulsen: "We found exciting evidence that P. fluorescens may
have acquired new clusters of genes, called genomic islands, by
means of lateral transfer from phages or other microbes."


###
The Institute for Genomic Research (TIGR) is a not-for-profit
research institute based in Rockville, Maryland. TIGR, which
sequenced the first complete genome of a free-living organism in
1995, has been at the forefront of the genomic revolution since the
institute was founded in 1992. TIGR conducts research involving the
structural, functional, and comparative analysis of genomes and gene
products in viruses, bacteria, archaea, and eukaryotes.

As the principal in-house research arm of the U.S. Department of
Agriculture, the Agricultural Research Service (ARS) conducts
research to develop and transfer solutions to agricultural problems
of high national priority and provides information access and
dissemination to ensure high-quality, safe food and other
agricultural products, assess the nutritional needs of Americans,
sustain a competitive agricultural economy, enhance the natural
resource base and the environment, and provide economic
opportunities for rural citizens, communities, and society as a
whole.

Oregon State University is known nationally and internationally for
the quality of its academic programs, its research excellence and
its service and outreach. OSU is one of only two universities in the
nation that are designated land grant, sea grant, space grant and
sun grant institutions.


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech
News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona
Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Biotechnology Forums:  http://www.arizonabiotech.com/index.php

Galapagos and Celera Genomics Sign Gene Function Analysis Agreement


ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005
Galapagos today announced that it has entered into a services
agreement with Celera Genomics Group (NYSE:CRA), an Applera
Corporation business. Under the agreement, Galapagos' services
division Galadeno will provide technology and adenoviral reagents
enabling Celera to analyze gene function in human cells and validate
potential drug targets. Galadeno will receive payments related to
its services and technology.Under the terms of the agreement,
Galadeno will construct recombinant adenoviruses harboring genes
selected by Celera. These custom-made viruses will be used to
introduce the genes into various cell types to evaluate their
function within biological pathways.





"We are delighted that Celera has decided to take advantage of
Galapagos' adenoviral technology. This service agreement will allow
Celera to utilize Galapagos' technology platform to perform cellular
assays and target validation studies in a very beneficial way," says
Onno van de Stolpe, CEO of Galapagos. "Our adenoviral platforms have
proven to deliver functionally validated drug targets for our
partners, opening significant opportunities for continued
collaboration. We are pleased that Celera has joined the growing
number of companies that choose Galapagos technology to study gene
function in human cells."

About Celera Genomics and Applera Corporation Applera Corporation
consists of two operating groups. The Celera Genomics Group is
engaged principally in the discovery and development of targeted
therapeutics for cancer, autoimmune and inflammatory diseases.
Celera Genomics is leveraging its proteomic, bioinformatic, and
genomic capabilities to identify and validate drug targets, and to
discover and develop small molecule therapeutics. It is also seeking
to advance therapeutic antibody and selected small molecule drug
programs in collaboration with global technology and market leaders.
The Applied Biosystems Group (NYSE:ABI) serves the life science
industry and research community by developing and marketing
instrument-based systems, consumables, software, and services.
Customers use these tools to analyze nucleic acids (DNA and RNA),
small molecules, and proteins to make scientific discoveries,
develop new pharmaceuticals, and conduct standardized testing.
Applied Biosystems is headquartered in Foster City, CA, and reported
sales of $1.7 billion during fiscal 2004. Celera Diagnostics, a
50/50 joint venture between Applied Biosystems and Celera Genomics,
is focused on discovery, development, and commercialization of
diagnostic products. Information about Applera Corporation,
including reports and other information filed by the company with
the Securities and Exchange Commission, is available at
www.applera.com, or by telephoning +1.800.762.6923. Information
about Celera Genomics is available at www.celera.com.

About Galapagos

Galapagos is a publicly traded, genomics-based drug discovery
company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that
has successfully discovered and validated novel targets in the bone
and joint diseases - osteoarthritis, osteoporosis and rheumatoid
arthritis, as well as in asthma and Alzheimer's disease. Proprietary
targets and compounds resulting from these programs are used for
Galapagos' internal drug discovery programs, combined with selected
out-licensing and partnering of projects during development.
Galadeno, Galapagos' services unit, provides reagents and functional
screens to leading pharmaceutical, biotech and nutraceutical
companies for rapid identification and validation of novel drug
targets. Galapagos currently employs 69 people, including 17 PhDs,
and occupies facilities in Mechelen, Belgium, and Leiden, The
Netherlands. Partners include Bayer, Boehringer Ingelheim, Celgene,
GlaxoSmithKline, Vertex and Wyeth.




http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

Rosetta Genomics Identifies Hundreds of Novel Human microRNAs, Study
Published in Nature Genetics Shows

- Novel approach identifies 89 novel new human microRNAs, nearly
doubling the number of human microRNAs sequenced to date, and
predicts number exceeds 800.
- First report of large number of primate specific microRNA,
postulated to play an important role in differentiation and
evolution.


REHOVOT, Israel, In a study published online this week and to be
published as a cover story in the July issue of Nature Genetics,
Rosetta Genomics' scientists report identification of hundreds of
human microRNA genes, including the first report of primate specific
microRNAs. Using a novel methodology, the researchers successfully
cloned and sequenced 89 human microRNAs, nearly doubling the number
sequenced in man to date.
MicroRNAs are a recently discovered class of tiny regulatory genes,
comprised in the 98% of the genome that does not encode proteins,
which until recently were considered 'Junk DNA'. Numerous recent
studies have shown microRNA genes, far from being 'junk', are in
fact of central importance, regulating at least 30% of all proteins,
and involved in a wide range of diseases, including diabetes,
obesity, viral diseases, and various types of cancer.

"The finding of large numbers of primate specific microRNAs is
exciting because it supports the notion that microRNAs may indeed
play an important role in the evolution of complexity of higher
organisms," said Aaron Ciechanover, Nobel prize laureate 2004, and
Chairman of Rosetta Genomics' Scientific Advisory Board. "We believe
that these genes may serve as an important basis for next generation
diagnostics and therapeutics."

"We are extremely pleased to report our success in nearly doubling
the number of human microRNAs sequenced to date, results which we
believe establish Rosetta Genomics as a leading player in discovery
of microRNA genes," said Isaac Bentwich MD, founder and chairman of
Rosetta Genomics and lead investigator of the study. "We are now
aggressively pursuing partnerships for development of diagnostics
and therapeutics based on this huge group of novel microRNAs."

About microRNAs

MicroRNAs are a recently discovered group of non-protein-coding
regulatory genes, shown to be involved in a wide range of diseases
in addition to neuronal and stem-cell differentiation. MicroRNAs
currently are an intensely researched area, and are believed
potentially to be the basis for a new class of therapeutic and
diagnostic products.

About Rosetta Genomics

Rosetta Genomics is a privately held genomics company, pioneering
the discovery and commercialization of microRNAs - a novel group of
regulatory genes, shown to be involved in a wide range of diseases
including diabetes, obesity and various types of cancer. Rosetta has
discovered and filed patents for the majority of microRNAs found to
date, and is in the process of developing diagnostics and
therapeutics based on these microRNAs, by both internal development
and collaborative partnerships.


      Rachel Spielman              Sharon Kaspi
      Ruder Finn                   Rosetta Genomics Media Relations
      Tel    +1 212 583 2714       Tel    +1 201 255 5900
      Mobile +1 646 872 2985       Mobile +1 201 255 5914
      spielmanr@...      sharon@...




---------------------------------------------------------------------
-----------
Source: Rosetta Genomics

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php